Johnson & Johnson (JNJ) 10-Q 4 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Oct. 02, 2016	Oct. 28, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	JOHNSON & JOHNSON
Entity Central Index Key	200,406
Current Fiscal Year End Date	--01-01
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Oct. 2, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		2,720,531,728

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Oct. 02, 2016	Jan. 03, 2016
Current assets:
Cash and cash equivalents	$ 18,205	$ 13,732
Marketable securities	22,228	24,644
Accounts receivable, trade, less allowances for doubtful accounts $267 (2015, $268)	11,798	10,734
Inventories (Note 2)	8,488	8,053
Prepaid expenses and other	2,600	3,047
Total current assets	63,319	60,210
Property, plant and equipment at cost	38,373	36,648
Less: accumulated depreciation	(22,278)	(20,743)
Property, plant and equipment, net	16,095	15,905
Intangible assets, net (Note 3)	27,642	25,764
Goodwill (Note 3)	23,171	21,629
Deferred taxes on income	5,897	5,490
Other assets	4,245	4,413
Total assets	140,369	133,411
Current liabilities:
Loans and notes payable	3,443	7,004
Accounts payable	5,971	6,668
Accrued liabilities	5,283	5,411
Accrued rebates, returns and promotions	5,181	5,440
Accrued compensation and employee related obligations	2,554	2,474
Accrued taxes on income	798	750
Total current liabilities	23,230	27,747
Long-term debt (Note 4)	23,546	12,857
Deferred taxes on income	3,193	2,562
Employee related obligations	8,217	8,854
Other liabilities	9,414	10,241
Total liabilities	67,600	62,261
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(12,715)	(13,165)
Retained earnings	108,860	103,879
Less: common stock held in treasury, at cost (397,259,000 and 364,681,000 shares)	26,496	22,684
Total shareholders’ equity	72,769	71,150
Total liabilities and shareholders' equity	$ 140,369	$ 133,411

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions	Oct. 02, 2016	Jan. 03, 2016
Current assets:
Allowances for doubtful accounts	$ 267	$ 268
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000	4,320,000
Common stock, shares issued	3,119,843	3,119,843
Treasury stock, shares	397,259	364,681

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Income Statement [Abstract]
Sales to customers (Note 9)	$ 17,820	$ 17,102	$ 53,784	$ 52,263
Sales to customers percent to sales	100.00%	100.00%	100.00%	100.00%
Cost of products sold	$ 5,486	$ 5,224	$ 16,151	$ 15,863
Cost of products sold percent to sales	30.80%	30.50%	30.00%	30.40%
Gross profit	$ 12,334	$ 11,878	$ 37,633	$ 36,400
Gross profit percent to sales	69.20%	69.50%	70.00%	69.60%
Selling, marketing and administrative expenses	$ 4,772	$ 5,081	$ 14,636	$ 15,312
Selling marketing and administrative expenses percent to sales	26.80%	29.70%	27.20%	29.30%
Research and development expense	$ 2,178	$ 2,154	$ 6,455	$ 6,182
Research and development expense percent to sales	12.20%	12.60%	12.00%	11.80%
In-process research and development	$ 0	$ 10	$ 29	$ 10
In-process research and development percent to sales	0.00%	0.10%	0.10%	0.00%
Interest income	$ (97)	$ (32)	$ (268)	$ (75)
Interest income percent to sales	(0.50%)	(0.20%)	(0.50%)	(0.10%)
Interest expense, net of portion capitalized	$ 192	$ 123	$ 542	$ 392
Interest expense, net of portion capitalized percent to sales	1.00%	0.70%	1.00%	0.70%
Other (income) expense, net	$ (54)	$ 420	$ 464	$ (859)
Other (income) expense, net percent to sales	(0.20%)	2.50%	0.90%	(1.60%)
Restructuring (Note 12)	$ 62	$ 0	$ 296	$ 0
Restructuring charge percent to sales	0.30%	0.00%	0.50%	0.00%
Earnings before provision for taxes on income	$ 5,281	$ 4,122	$ 15,479	$ 15,438
Earnings before provision for taxes on income percent to sales	29.60%	24.10%	28.80%	29.50%
Provision for taxes on income (Note 5)	$ 1,009	$ 764	$ 2,753	$ 3,244
Provision for taxes on income perent to sales	5.60%	4.50%	5.10%	6.20%
NET EARNINGS	$ 4,272	$ 3,358	$ 12,726	$ 12,194
Net earnings percent to sales	24.00%	19.60%	23.70%	23.30%
NET EARNINGS PER SHARE (Note 8)
Basic (per share)	$ 1.56	$ 1.21	$ 4.64	$ 4.39
Diluted (per share)	1.53	1.20	4.55	4.33
CASH DIVIDENDS PER SHARE	$ 0.80	$ 0.75	$ 2.35	$ 2.20
AVG. SHARES OUTSTANDING
Basic (shares)	2,731.6	2,768.4	2,744.9	2,774.8
Diluted (shares)	2,785.4	2,807.2	2,796.6	2,817.1

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Statement of Comprehensive Income [Abstract]
Net earnings	$ 4,272	$ 3,358	$ 12,726	$ 12,194
Other comprehensive income (loss), net of tax
Foreign currency translation	(94)	(1,069)	490	(2,729)
Securities:
Unrealized holding gain (loss) arising during period	29	(44)	129	267
Reclassifications to earnings	(42)	(46)	(136)	(127)
Net change	(13)	(90)	(7)	140
Employee benefit plans:
Prior service cost amortization during period	(5)	(5)	(15)	(16)
Gain (loss) amortization during period	103	159	310	477
Net change	98	154	295	461
Derivatives & hedges:
Unrealized gain (loss) arising during period	4	160	(437)	26
Reclassifications to earnings	(3)	38	109	(37)
Net change	1	198	(328)	(11)
Other comprehensive income (loss)	(8)	(807)	450	(2,139)
Comprehensive income	$ 4,264	$ 2,551	$ 13,176	$ 10,055

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Consolidated Statement of Comprehensive Income [Abstract]
Securities	$ 7	$ 48	$ 4	$ 76
Employee Benefits	51	75	155	226
Derivatives & Hedges	$ 0	$ 107	$ 177	$ 6

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015
CASH FLOW FROM OPERATING ACTIVITIES
Net earnings	$ 12,726	$ 12,194
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	2,699	2,713
Stock based compensation	704	677
Asset write-downs	187	367
Net gain on sale of assets/businesses	(276)	(1,274)
Deferred tax provision	215	233
Accounts receivable allowances	(10)	2
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(736)	(910)
Increase in inventories	(408)	(719)
Decrease in accounts payable and accrued liabilities	(1,220)	(1,271)
(Increase)/Decrease in other current and non-current assets	(379)	986
(Decrease)/Increase in other current and non-current liabilities	(1,388)	1,486
NET CASH FLOWS FROM OPERATING ACTIVITIES	12,114	14,484
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(2,133)	(2,097)
Proceeds from the disposal of assets/businesses, net	873	1,620
Acquisitions, net of cash acquired	(4,050)	(233)
Purchases of investments	(27,677)	(28,766)
Sales of investments	30,437	23,167
Other	(37)	(35)
NET CASH USED BY INVESTING ACTIVITIES	(2,587)	(6,344)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(6,451)	(6,101)
Repurchase of common stock	(6,954)	(3,394)
Proceeds from short-term debt	149	2,107
Retirement of short-term debt	(3,926)	(930)
Proceeds from long-term debt, net of issuance costs	11,951	3
Retirement of long-term debt	(953)	(27)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	1,112	550
Other	(15)	(50)
NET CASH USED BY FINANCING ACTIVITIES	(5,087)	(7,842)
Effect of exchange rate changes on cash and cash equivalents	33	(1,182)
Increase/(Decrease) in cash and cash equivalents	4,473	(884)
Cash and Cash equivalents, beginning of period	13,732	14,523
CASH AND CASH EQUIVALENTS, END OF PERIOD	18,205	13,639
Acquisitions
Fair value of assets acquired	4,094	477
Fair value of liabilities assumed and noncontrolling interests	(44)	(244)
Net cash paid for acquisitions	$ 4,050	$ 233

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Oct. 02, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016 . The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. New Accounting Pronouncements Recently Adopted Accounting Pronouncements During the fiscal first quarter of 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-09 Compensation - Stock Compensation: Improvements to Employee Share Based Payment Accounting. The amendments in the update are effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. During the fiscal second quarter of 2016, the Company elected to early adopt this standard. The update requires the following changes to presentation of the financial statements: • All excess tax benefits and deficiencies to be recognized as a reduction or an increase to the provision for taxes on income. Previously, the Company recorded these benefits directly to Retained Earnings. The tax benefit for the Company was $47 million and $335 million for the fiscal third quarter and fiscal nine months ended for 2016, respectively. The standard does not permit retroactive presentation of this benefit to prior fiscal years on the Consolidated Statement of Earnings. • The tax benefit or deficiency is required to be classified and presented as a cash flow to/from operating activities. It was previously required to be presented as a cash flow to/from financing activities on the Consolidated Statement of Cash Flows. As permitted in the standard, the Company has elected to adopt this reclassification on a prospective basis and therefore prior fiscal years for the Consolidated Statement of Cash Flows have not been recast for this provision. • Clarifies that all cash payments made to taxing authorities on employees’ share-based compensation should be classified as a cash outflow from financing activities. This reclassification is required to be recast retrospectively. As a result, for the fiscal nine months of 2016, $264 million was classified as a cash outflow from financing activities and for the fiscal nine months of 2015, $287 million of cash outflow was reclassified from an operating activity to a financing activity (Proceeds from the exercise of stock options/employee withholding tax on stock awards, net). • In the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit. This did not have a material impact on the Company's diluted net earnings per share calculation. During the fiscal third quarter of 2015, the FASB issued Accounting Standards Update 2015-16 Business Combinations: Simplifying the Accounting for Measurement-Period Adjustments. The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This update is effective for the Company for all annual and interim periods beginning after December 15, 2015. The amendments in this update should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update with earlier application permitted for financial statements that have not been issued. This update did not have a material impact on the Company’s consolidated financial statements. During the fiscal second quarter of 2015, the FASB issued Accounting Standards Update 2015-03: Simplifying the Presentation of Debt Issuance Costs. This update requires capitalized debt issuance costs to be presented as a reduction to the carrying value of debt instead of being classified as a deferred charge, as currently required. This update is effective for the Company for all annual and interim periods beginning after December 15, 2015 and is required to be applied retroactively for all periods presented. This update did not have a material impact on the presentation of the Company’s financial position. During the fiscal second quarter of 2014, the FASB issued amended guidance Accounting Standards Update No. 2014-10: Development Stage Entities: Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entity Guidance in Topic 810, Consolidation. The change in the current guidance will require the Company to determine if it should consolidate one of these entities based on the change in the consolidation analysis. This update to the consolidation analysis became effective for all annual periods and interim reporting periods beginning after December 15, 2015. The adoption of this standard did not have a material impact on the presentation of the Company's consolidated financial statements. Recently Issued Accounting Standards Not Adopted as of October 2, 2016 In October 2016, the FASB issued Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. This update removes the current exception in US GAAP prohibiting entities from recognizing current and deferred income tax expenses or benefits related to transfer of assets, other than inventory, within the consolidated entity. The current exception to defer the recognition of any tax impact on the transfer of inventory within the consolidated entity until it is sold to a third party remains unaffected. The amendments in this update are effective for public entities for annual reporting periods beginning after December 15, 2017. Early adoption is permitted and should be in the first interim period if an entity issues interim financial statements. The Company is currently assessing the impact of the future adoption of this standard on its consolidated financial statements. During the fiscal third quarter of 2016, the FASB issued Accounting Standards Update 2016-15 Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This update addresses whether to present certain specific cash flow items as operating, investing or financing activities. The amendments in this update are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. The Company is currently assessing the impact of the future adoption of this standard on its consolidated Statements of Cash Flows. During the fiscal first quarter of 2016, the FASB issued Accounting Standards Update 2016-07 Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The amendments in the update eliminate the requirement that when an investment qualifies for the use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step by step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The amendments should be applied prospectively upon their effective date to increases in the level of ownership interest or degree of influence that result in the application of the equity method. Earlier adoption is permitted for any entity in any interim or annual period. The adoption of this standard is not expected to have a material impact on the presentation of the Company's consolidated financial statements. During the fiscal first quarter of 2016, the FASB issued Accounting Standards Update 2016-02 Leases (Topic 842). This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company is currently assessing the impact of the future adoption of this standard on its financial statements. During the fiscal first quarter of 2016, the FASB issued Accounting Standards Update 2016-01 Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments in this update supersede the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and require equity securities to be measured at fair value with changes in the fair value recognized through net income. The standard amends financial reporting by providing relevant information about an entity’s equity investments and reducing the number of items that are recognized in other comprehensive income. This update will be effective for the Company for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is unable to estimate the impact of the future adoption of this standard on its financial statements as it will depend on the equity investments as of the adoption date. During the fiscal second quarter of 2015, the FASB issued Accounting Standards Update 2015-11: Simplifying the Measurement of Inventory. This update requires inventory to be measured at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2016. The amendments in this update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. This update will not have a material impact on the presentation of the Company’s financial position. During the fiscal second quarter of 2014, the FASB issued Accounting Standards Update 2014-09: Revenue from Contracts with Customers. This standard replaces substantially all current revenue recognition accounting guidance. During the fiscal third quarter of 2015, the FASB approved a one year deferral to the effective date to be adopted by all public companies for all annual periods and interim reporting periods beginning after December 15, 2017. During the fiscal first quarter of 2016, the FASB issued additional guidance and clarification relating to Identifying Performance Obligations, Licensing, and Principal versus Agent Considerations. During the second quarter of 2016, the FASB issued additional guidance and clarification relating to assessing collectability, presentation of sales taxes, noncash consideration, and contract modifications & completed contracts at transition. Early adoption of this standard is permitted but not before the original effective date for all annual periods and interim reporting periods beginning after December 15, 2016. The Company is currently assessing the impact of the future adoption of this standard on its financial statements. During the fiscal third quarter of 2014, the FASB issued Accounting Standards Update No. 2014-15: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This standard requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management’s plan to alleviate these doubts are required. This update will become effective for all annual periods and interim reporting periods ending after December 15, 2016. This standard is not expected to have any impact on current disclosures in the financial statements.

Inventories

Inventories	9 Months Ended
	Oct. 02, 2016
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) October 2, 2016 January 3, 2016 Raw materials and supplies $ 974 936 Goods in process 1,859 2,241 Finished goods 5,655 4,876 Total inventories $ 8,488 8,053

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Oct. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2015 . Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) October 2, 2016 January 3, 2016 Intangible assets with definite lives: Patents and trademarks — gross $ 10,815 8,299 Less accumulated amortization 5,017 4,745 Patents and trademarks — net 5,798 3,554 Customer relationships and other intangibles — gross 17,830 17,583 Less accumulated amortization 6,411 5,816 Customer relationships and other intangibles — net 11,419 11,767 Intangible assets with indefinite lives: Trademarks 7,042 7,023 Purchased in-process research and development 3,383 3,420 Total intangible assets with indefinite lives 10,425 10,443 Total intangible assets — net $ 27,642 25,764 Goodwill as of October 2, 2016 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at January 3, 2016 $ 7,240 2,889 11,500 21,629 Goodwill, related to acquisitions 1,332 — 180 1,512 Goodwill, related to divestitures (24 ) (10 ) — (34 ) Currency translation/Other 27 15 22 64 Goodwill, net at October 2, 2016 $ 8,575 2,894 11,702 23,171 The weighted average amortization periods for patents and trademarks and customer relationships and other intangible assets are 19 years and 24 years, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $895 million and $912 million for the fiscal nine months ended October 2, 2016 and September 27, 2015 , respectively. The estimated amortization expense for the five succeeding years approximates $1.3 billion , before tax, per year. Intangible asset write-downs are included in Other (income) expense, net. The primary driver of the increase to intangible assets and goodwill is the Vogue International LLC acquisition in the fiscal third quarter of 2016, which resulted in the recording of $2.3 billion to intangible assets and $1.1 billion to goodwill. The intangible assets and goodwill amounts related to the Vogue acquisition are based on the preliminary purchase price allocation. See Note 10 to the Consolidated Financial Statements for additional details on the Vogue acquisition.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 02, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. The Company also uses equity collar contracts to manage exposure to market risk associated with certain equity investments. All three types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features or requirements to post collateral (excluding equity collar contracts) by either the Company or the counter-party. For equity collar contracts, the Company pledged the underlying hedged marketable equity securities to the counter-party as collateral. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October 2, 2016 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps, interest rate swaps and equity collar contracts of $35.0 billion , $2.3 billion , $2.2 billion , and $0.4 billion respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Changes in the fair value of a derivative that is designated as a cash flow hedge and is highly effective are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is included in current period earnings in Other (income) expense, net for forward foreign exchange contracts, cross currency interest rate swaps, net investment hedges and equity collar contracts. For interest rate swaps designated as fair value hedges, hedge ineffectiveness, if any, is included in current period earnings within interest expense. For the current reporting period, hedge ineffectiveness associated with interest rate swaps was not material. During the fiscal second quarter of 2016, the Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. During the fiscal third quarter of 2016, the change in the carrying value due to remeasurement of these Euro notes resulted in a $76 million pretax gain reflected in foreign currency translation adjustment, within the Consolidated Statements of Comprehensive Income. As of October 2, 2016 , the balance of deferred net losses on derivatives included in accumulated other comprehensive income was $364 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts, net investment hedges and equity collar contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal third quarters in 2016 and 2015 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Third Quarters Ended Cash Flow Hedges By Income Statement Caption October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 Sales to customers (3) $ (12 ) 3 (8 ) (24 ) (1 ) (3 ) Cost of products sold (3) (4 ) 222 13 (34 ) (4 ) 1 Research and development expense (3) (5 ) (10 ) (2 ) 7 1 — Interest (income)/Interest expense, net (4) 29 (13 ) 12 1 — — Other (income) expense, net (3) (5) (4 ) (42 ) (12 ) 12 — (1 ) Total $ 4 160 3 (38 ) (4 ) (3 ) The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal nine months in 2016 and 2015 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Nine Months Ended Cash Flow Hedges By Income Statement Caption October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 Sales to customers (3) $ (39 ) (52 ) (29 ) (95 ) (1 ) (5 ) Cost of products sold (3) (226 ) 106 5 82 (10 ) 15 Research and development expense (3) (100 ) (13 ) (98 ) (2 ) — — Interest (income)/Interest expense, net (4) 38 (42 ) 27 (2 ) — — Other (income) expense, net (3) (5) (110 ) 27 (14 ) 54 (3 ) — Total $ (437 ) 26 (109 ) 37 (14 ) 10 All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps (5) Includes equity collar contracts For the fiscal third quarters ended October 2, 2016 and September 27, 2015 , a gain of $35 million and a loss of $8 million , respectively, was recognized in Other (income) expense, net, relating to forward foreign exchange contracts not designated as hedging instruments. For the fiscal nine months ended October 2, 2016 and September 27, 2015 , a loss of $6 million and a gain of $32 million , respectively, was recognized in Other (income) expense, net, relating to forward foreign exchange contracts not designated as hedging instruments. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company did not have any other significant financial assets or liabilities which would require revised valuations under this standard that are recognized at fair value. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of October 2, 2016 and January 3, 2016 were as follows: October 2, 2016 January 3, 2016 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) $ — 222 — 222 452 Interest rate contracts (2)(4)(7) — 50 — 50 28 Total — 272 — 272 480 Liabilities: Forward foreign exchange contracts (8) — 542 — 542 358 Interest rate contracts (3)(4)(8) — 309 — 309 241 Equity collar contracts (8)(9) — 95 — 95 — Total — 946 — 946 599 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts (7) — 14 — 14 33 Liabilities: Forward foreign exchange contracts (8) — 33 — 33 41 Available For Sale Other Investments: Equity investments (5) 1,332 — — 1,332 1,494 Debt securities (6) $ — 12,237 — 12,237 8,316 (1) 2015 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,494 million , which are classified as Level 1. (2) Includes $35 million and $20 million of non-current other assets for October 2, 2016 and January 3, 2016, respectively. (3) Includes $309 million and $239 million of non-current other liabilities for October 2, 2016 and January 3, 2016, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets with the exception of $345 million of current other assets for October 2, 2016 . The carrying amount of the equity investments were $544 million and $528 million as of October 2, 2016 and January 3, 2016, respectively. The unrealized gains were $802 million and $979 million as of October 2, 2016 and January 3, 2016, respectively. The unrealized losses were $14 million and $13 million as of October 2, 2016 and January 3, 2016, respectively. (6) Classified as current marketable securities. (7) Classified as other current assets. (8) Classified as accounts payable. (9) Includes $16 million of non-current other liabilities for October 2, 2016 . The Company's cash, cash equivalents and current marketable securities as of October 2, 2016 comprised: October 2, 2016 (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 1,971 — — 1,971 1,971 U.S. Gov't Securities (1) 10,498 1 — 10,499 6,997 3,501 Other Sovereign Securities (1) 3,385 — — 3,385 952 2,433 U.S. Reverse repurchase agreements (1) 5,883 — — 5,883 4,882 1,001 Other Reverse repurchase agreements (1) 96 — — 96 96 Corporate debt securities (1) 3,501 1 — 3,502 790 2,711 Money market funds 1,448 — — 1,448 1,448 Time deposits (1) 1,069 — — 1,069 1,069 Subtotal 27,851 2 — 27,853 18,205 9,646 Unrealized Gain Unrealized Loss Gov't securities 10,235 120 (1 ) 10,354 — 10,354 Other Sovereign Securities 91 — — 91 — 91 Corporate debt securities 1,782 11 (1 ) 1,792 — 1,792 Equity investments 50 314 (19 ) 345 — 345 Subtotal Available for Sale (2) $ 12,158 445 (21 ) 12,582 — 12,582 Total cash, cash equivalents and current marketable securities 18,205 22,228 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as current marketable securities. The estimated fair value was the same as the amortized cost as of January 3, 2016. The contractual maturities of the available for sale securities at October 2, 2016 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 475 475 Due after one year through five years 11,445 11,575 Due after five years through ten years 188 187 Total debt securities $ 12,108 12,237 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October 2, 2016 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 3,443 3,443 Non-Current Debt 1.125% Notes due 2017 703 705 5.15% Debentures due 2018 899 958 1.65% Notes due 2018 608 616 4.75% Notes due 2019 (1B Euro 1.1198) 1,115 1,287 1.875% Notes due 2019 511 524 0.89% Notes due 2019 299 300 1.125% Notes due 2019 699 700 3% Zero Coupon Convertible Subordinated Debentures due in 2020 94 152 2.95% Debentures due 2020 545 578 3.55% Notes due 2021 447 491 2.45% Notes due 2021 349 367 1.65% Notes due 2021 997 1,013 0.250% Notes due 2022 (1B Euro 1.1198) 1,116 1,132 6.73% Debentures due 2023 249 335 3.375% Notes due 2023 807 875 2.05% Notes due 2023 497 507 0.650% Notes due 2024 (750MM Euro 1.1198) 834 863 5.50% Notes due 2024 (500 MM GBP 1.3000) 643 868 2.45% Notes due 2026 1,989 2,059 1.150% Notes due 2028 (750MM Euro 1.1198) 830 886 6.95% Notes due 2029 296 440 4.95% Debentures due 2033 497 635 4.375% Notes due 2033 857 1,026 1.650% Notes due 2035 (1.5B Euro 1.1198) 1,660 1,884 3.55% Notes due 2036 987 1,098 5.95% Notes due 2037 991 1,457 5.85% Debentures due 2038 695 1,016 4.50% Debentures due 2040 537 674 4.85% Notes due 2041 296 390 4.50% Notes due 2043 495 624 3.70% Notes due 2046 1,970 2,213 Other 34 34 Total Non-Current Debt $ 23,546 26,707 The weighted average effective interest rate on non-current debt is 3.14% . The excess of the estimated fair value over the carrying value of debt was $1.7 billion at January 3, 2016. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	9 Months Ended
	Oct. 02, 2016
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal nine months of 2016 and 2015 were 17.8% and 21.0% , respectively. In the fiscal nine months of 2016, the Company had higher income in lower tax jurisdictions relative to higher tax jurisdictions as compared to 2015, which decreased the effective tax rate by approximately 0.8% . As described in Note 1, the Company has adopted a new accounting standard for the reporting of tax benefits on share-based compensation. The adoption of this new standard reduced the tax rate for the first nine months of fiscal 2016 by approximately 2.0% versus 2015. The remainder of the change in the effective tax rate from prior year was primarily related to the U.S. Research & Development tax credit and the Controlled Foreign Corporation look-through provisions, which were not enacted into law until the fiscal fourth quarter of 2015, and the settlement of several uncertain tax positions in international jurisdictions. As of October 2, 2016 , the Company had approximately $3.1 billion of liabilities from unrecognized tax benefits. The Company believes it is possible that audits may be completed by tax authorities in some jurisdictions over the next twelve months. The Company is not able to provide a reasonably reliable estimate of the timing of any future tax payments relating to uncertain tax positions.

Pensions and Other Postretireme

Pensions and Other Postretirement Benefits	9 Months Ended
	Oct. 02, 2016
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits	PENSIONS AND OTHER POSTRETIREMENT BENEFITS Components of Net Periodic Benefit Cost Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal third quarters of 2016 and 2015 include the following components: Fiscal Third Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 Service cost $ 224 247 56 64 Interest cost 232 246 39 46 Expected return on plan assets (490 ) (451 ) (1 ) (2 ) Amortization of prior service cost/(credit) 2 — (9 ) (8 ) Recognized actuarial losses 123 186 33 50 Curtailments and settlements 6 — — — Net periodic benefit cost $ 97 228 118 150 Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal nine months of 2016 and 2015 include the following components: Fiscal Nine Months Ended Retirement Plans Other Benefit Plans (Dollars in Millions) October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 Service cost $ 676 744 166 193 Interest cost 698 743 118 139 Expected return on plan assets (1,475 ) (1,361 ) (4 ) (5 ) Amortization of prior service cost/(credit) 2 1 (25 ) (25 ) Recognized actuarial losses 371 560 101 150 Curtailments and settlements 11 4 — — Net periodic benefit cost $ 283 691 356 452 Company Contributions For the fiscal nine months ended October 2, 2016 , the Company contributed $372 million and $21 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Oct. 02, 2016
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 3, 2016 $ (8,435 ) 604 (5,298 ) (36 ) (13,165 ) Net change 490 (7 ) 295 (328 ) 450 October 2, 2016 $ (7,945 ) 597 (5,003 ) (364 ) (12,715 ) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Oct. 02, 2016
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal third quarters ended October 2, 2016 and September 27, 2015 : Fiscal Third Quarters Ended (Shares in Millions) October 2, 2016 September 27, 2015 Basic net earnings per share $ 1.56 1.21 Average shares outstanding — basic 2,731.6 2,768.4 Potential shares exercisable under stock option plans 140.8 129.4 Less: shares which could be repurchased under treasury stock method (88.4 ) (92.8 ) Convertible debt shares 1.4 2.2 Average shares outstanding — diluted 2,785.4 2,807.2 Diluted net earnings per share $ 1.53 1.20 The diluted net earnings per share calculation for both the fiscal third quarters ended October 2, 2016 and September 27, 2015 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal third quarter ended October 2, 2016 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive. The diluted net earnings per share calculation for the fiscal third quarter ended September 27, 2015 excluded 20 million shares related to stock options, as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share. The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal nine months ended October 2, 2016 and September 27, 2015 : Fiscal Nine Months Ended (Shares in Millions) October 2, 2016 September 27, 2015 Basic net earnings per share $ 4.64 4.39 Average shares outstanding — basic 2,744.9 2,774.8 Potential shares exercisable under stock option plans 144.0 129.1 Less: shares which could be repurchased under treasury stock method (93.7 ) (89.0 ) Convertible debt shares 1.4 2.2 Average shares outstanding — diluted 2,796.6 2,817.1 Diluted net earnings per share $ 4.55 4.33 The diluted net earnings per share calculation for both the fiscal nine months ended October 2, 2016 and September 27, 2015 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal nine months ended October 2, 2016 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive. The diluted net earnings per share calculation for the fiscal nine months ended September 27, 2015 excluded 20 million shares related to stock options, as the exercise price of these options was greater than their average market value, which would result in an anti-dilutive effect on diluted earnings per share.

Segments of Business and Geogra

Segments of Business and Geographic Areas	9 Months Ended
	Oct. 02, 2016
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal Third Quarters Ended (Dollars in Millions) October 2, September 27, Percent Change Consumer United States $ 1,291 1,277 1.1 % International 1,970 2,037 (3.3 ) Total 3,261 3,314 (1.6 ) Pharmaceutical United States 5,042 4,509 11.8 International 3,358 3,185 5.4 Total 8,400 7,694 9.2 Medical Devices United States 3,048 3,005 1.4 International 3,111 3,089 0.7 Total 6,159 6,094 1.1 Worldwide United States 9,381 8,791 6.7 International 8,439 8,311 1.5 Total $ 17,820 17,102 4.2 % Fiscal Nine Months Ended (Dollars in Millions) October 2, September 27, Percent Change Consumer United States $ 4,033 3,991 1.1 % International 5,842 6,196 (5.7 ) Total 9,875 10,187 (3.1 ) Pharmaceutical United States 15,123 13,423 12.7 International 10,109 9,943 1.7 Total 25,232 23,366 8.0 Medical Devices United States 9,118 8,980 1.5 International 9,559 9,730 (1.8 ) Total 18,677 18,710 (0.2 ) Worldwide United States 28,274 26,394 7.1 International 25,510 25,869 (1.4 ) Total $ 53,784 52,263 2.9 % INCOME BEFORE TAX BY SEGMENT Fiscal Third Quarters Ended (Dollars in Millions) October 2, September 27, Percent Change Consumer (1) $ 679 811 (16.3 )% Pharmaceutical (2) 3,309 2,732 21.1 Medical Devices (3) 1,526 835 82.8 Segments operating profit 5,514 4,378 25.9 Less: Expense not allocated to segments (4) 233 256 Worldwide income before tax $ 5,281 4,122 28.1 % Fiscal Nine Months Ended (Dollars in Millions) October 2, 2016 September 27, 2015 Percent Change Consumer (1) $ 1,816 1,772 2.5 % Pharmaceutical (2) 10,340 9,816 5.3 Medical Devices (3) 4,041 4,640 (12.9 ) Segments operating profit 16,197 16,228 (0.2 ) Less: Expense not allocated to segments (4) 718 790 Worldwide income before taxes $ 15,479 15,438 0.3 % (1) Includes a gain of $229 million from the divestiture of the SPLENDA ® brand recorded in the fiscal third quarter and fiscal nine months of 2015. (2) Includes litigation expense of $136 million recorded in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution. Includes a positive adjustment of $513 million and $462 million to previous reserve estimates in the fiscal nine months of 2016 and 2015, respectively. (3) Includes a restructuring related charge of $109 million and $387 million in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $55 million and $731 million recorded in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $409 million in the fiscal third quarter of 2015. Includes a $346 million intangible asset write-down related to Acclarent recorded in the fiscal third quarter and fiscal nine months of 2015. The fiscal nine months of 2015 included $148 million for costs associated with the DePuy ASR TM Hip program. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal Third Quarters Ended (Dollars in Millions) October 2, 2016 September 27, 2015 Percent Change United States $ 9,381 8,791 6.7 % Europe 3,832 3,802 0.8 Western Hemisphere, excluding U.S. 1,396 1,463 (4.6 ) Asia-Pacific, Africa 3,211 3,046 5.4 Total $ 17,820 17,102 4.2 % Fiscal Nine Months Ended (Dollars in Millions) October 2, 2016 September 27, 2015 Percent Change United States $ 28,274 26,394 7.1 % Europe 11,769 11,993 (1.9 ) Western Hemisphere, excluding U.S. 4,269 4,603 (7.3 ) Asia-Pacific, Africa 9,472 9,273 2.1 Total $ 53,784 52,263 2.9 %

Business Combinations and Dives

Business Combinations and Divestitures	9 Months Ended
	Oct. 02, 2016
Business Combinations [Abstract]
Business Combinations and Divestitures	BUSINESS COMBINATIONS AND DIVESTITURES During the fiscal third quarter of 2016, the Company completed the acquisition of Vogue International LLC, a privately-held company focused on the marketing, development and distribution of salon-influenced and nature inspired hair care and other personal products for $3.3 billion in cash. The net purchase price of $3.3 billion was primarily recorded as amortizable intangible assets for $2.3 billion and goodwill for $1.1 billion . The weighted average life for the $2.3 billion of total amortizable intangibles is approximately 22 years . The trademark asset values were determined to have definite lives ranging from 10 to 22 years, with the majority being 22 years. The customer relationship asset values were determined to have definite lives of 15 years. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is expected to be deductible for tax purposes. The intangible assets and goodwill amounts are based on the preliminary purchase price allocation. The assets acquired were recorded in the Consumer segment. During the fiscal third quarter of 2016, the company announced a definitive agreement to acquire Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, for $4.325 billion in cash. The acquisition will include ophthalmic products related to: cataract surgery, laser refractive surgery and consumer eye health. The transaction is expected to close in the first quarter of 2017. The closing is subject to antitrust clearance and other customary closing conditions. During the fiscal second quarter of 2016, the Company completed the acquisitions of NeuWave Medical, Inc., a privately-held medical device company that manufactures and markets minimally invasive soft tissue microwave ablation systems and NeoStrata Company, Inc., a global leader in dermocosmetics. Additionally, during the fiscal second quarter of 2016, the Company completed the divestiture of its controlled substance raw material and active pharmaceutical ingredient (API) business. The proceeds from the divestiture were $650 million . During the fiscal third quarter of 2015, the Company completed the divestiture of its SPLENDA ® brand. The pre-tax gain on the divestiture was $229 million and was recognized in Other (income) expense, net. During the fiscal second quarter of 2015, the Company completed the divestiture of its U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution for approximately $1.05 billion . The pre-tax gain on the divestiture was $981 million and was recognized in Other (income) expense, net. During the fiscal first quarter of 2015, the Company acquired XO1 Limited, a privately-held biopharmaceutical company developing an anti-thrombin antibody.

Legal Proceedings

Legal Proceedings	9 Months Ended
	Oct. 02, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of October 2, 2016 , the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors, including whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; or there are numerous parties involved. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, the PINNACLE ® Acetabular Cup System, pelvic meshes, RISPERDAL ® , XARELTO ® and JOHNSON'S ® Baby Powder. As of October 2, 2016 , in the U.S. there were approximately 2,900 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System, 9,300 with respect to the PINNACLE ® Acetabular Cup System, 53,400 with respect to pelvic meshes, 15,400 with respect to RISPERDAL ® , 15,600 with respect to XARELTO ® and 2,400 with respect to JOHNSON'S ® Baby Powder. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR ™ Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. This settlement covered approximately 8,000 patients. In February 2015, DePuy reached an additional agreement, which effectively extends the existing settlement program to ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 1, 2015. This second agreement is estimated to cover approximately 1,800 additional patients. The estimated cost of these agreements is covered by existing accruals. This settlement program is expected to bring to a close significant ASR Hip litigation activity in the United States. However, many lawsuits in the United States will remain, and the settlement program does not address litigation outside of the United States. In Australia, a settlement has been reached with representatives of a class action lawsuit pending in the Federal Court of New South Wales that resolves the claims of the majority of ASR Hip patients in that country. The Company continues to receive information with respect to potential costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the DePuy ASR™ Hip program and related product liability litigation. Changes to these accruals may be required in the future as additional information becomes available. Claims for personal injury have also been made against DePuy and Johnson & Johnson relating to DePuy's PINNACLE ® Acetabular Cup System used in hip replacement surgery. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom. The Company has established an accrual for defense costs in connection with product liability litigation associated with DePuy's PINNACLE ® Acetabular Cup System. Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Southern District of West Virginia. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, Italy and Venezuela, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. The Company has established an accrual with respect to product liability litigation associated with Ethicon's pelvic mesh products. Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism, and related compounds. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established an accrual with respect to product liability litigation associated with RISPERDAL ® . Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of XARELTO ® , an oral anticoagulant. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania; and there are coordinated proceedings in Delaware, California and Missouri. Class action lawsuits also have been filed in Canada. The Company has established an accrual for defense costs in connection with product liability litigation associated with XARELTO ® . Changes to this accrual may be required in the future as additional information becomes available. Claims for personal injury have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of JOHNSON'S ® Baby Powder. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California. In addition, a federal multi-district litigation proceeding has been created for this litigation in the District Court of New Jersey. The Company has established an accrual for defense costs in connection with product liability litigation associated with JOHNSON'S ® Baby Powder. Changes to this accrual may be required in the future as additional information becomes available. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In November 2007, Roche Diagnostics Operations, Inc., et al. (Roche) filed a patent infringement lawsuit against LifeScan, Inc. (LifeScan) in the United States District Court for the District of Delaware, alleging LifeScan's OneTouch ® Line of Blood Glucose Monitoring Systems infringe two patents related to the use of microelectrode sensors. Roche is seeking monetary damages and injunctive relief. In September 2009, LifeScan obtained a favorable ruling on claim construction that precluded a finding of infringement. Roche appealed and the Court of Appeals reversed the District Court's ruling on claim construction and remanded the case to the District Court for new findings on the issue. In December 2014, the District Court ruled in LifeScan's favor, reinstated the original claim construction and dismissed the case. Roche appealed, and in September 2016, the Court of Appeals affirmed the District Court's ruling. In June 2009, Rembrandt Vision Technologies, L.P. (Rembrandt) filed a patent infringement lawsuit against Johnson & Johnson Vision Care, Inc. (JJVC) in the United States District Court for the Eastern District of Texas alleging that JJVC's manufacture and sale of its ACUVUE ADVANCE ® and ACUVUE OASYS ® Hydrogel Contact Lenses infringe their U.S. Patent No. 5,712,327 (the '327 patent). Rembrandt is seeking monetary relief. The case was transferred to the United States District Court for the Middle District of Florida. In May 2012, the jury returned a verdict holding that neither of the accused lenses infringes the '327 patent. Rembrandt appealed, and in August 2013, the United States Court of Appeals for the Federal Circuit affirmed the District Court's judgment. Rembrandt asked the District Court to grant it a new trial based on alleged new evidence, and in July 2014, the District Court denied Rembrandt’s motion. Rembrandt appealed and the Court of Appeals overturned that ruling in April 2016 and remanded the case to the District Court for a new trial. JJVC's motion to reconsider was denied; and JJVC has filed a petition for review with the United States Supreme Court. In December 2009, the State of Israel filed a lawsuit in the District Court in Tel Aviv Jaffa against Omrix Biopharmaceuticals, Inc. and various affiliates (Omrix). In the lawsuit, the State claims that an employee of a government-owned hospital was the inventor on several patents related to fibrin glue technology that the employee developed while he was a government employee. The State claims that he had no right to transfer any intellectual property to Omrix because it belongs to the State. The State is seeking damages plus royalties on QUIXIL™ and EVICEL ® products, or alternatively, transfer of the patents to the State. The case remains active, but no trial date has been set. In September 2011, LifeScan, Inc. (LifeScan) filed a lawsuit against Shasta Technologies, LLC (Shasta), Instacare Corp (now Pharmatech Solutions, Inc. (Pharmatech)) and Conductive Technologies, Inc. (Conductive) in the United States District Court for the Northern District of California for patent infringement and false advertising for the making and marketing of a strip for use in LifeScan's OneTouch ® Blood Glucose Meters. The defendants alleged that the three LifeScan patents-in-suit are invalid and challenged the validity of the asserted patents in the United States Patent and Trademark Office (USPTO). In April 2013, the defendants brought counterclaims for alleged antitrust violations and false advertising and those claims were stayed pending resolution of the patent infringement case. The validity of two of the patents was confirmed by the USPTO, but the USPTO determined that the third patent, U.S. Patent No. 7,250,105, is invalid. LifeScan lost an appeal of that decision, but is seeking a rehearing. LifeScan entered into a settlement agreement with Shasta and Conductive. A motion brought by Pharmatech for summary judgment of patent invalidity was denied. In April 2016, LifeScan and Pharmatech entered into a settlement agreement and the case was dismissed. LifeScan filed a patent infringement lawsuit against UniStrip Technologies, LLC (UniStrip) in the United States District Court for the District of North Carolina in May 2014, alleging that the making and marketing of UniStrip’s strips for use in LifeScan’s blood glucose monitors infringe U.S. Patent Nos. 6,241,862 (the ‘862 patent) and 7,250,105 (the ‘105 patent). In August 2014, the USPTO determined that the ‘105 patent is invalid. In January 2016, the invalidity decision was upheld on appeal. LifeScan filed a motion for rehearing, which was denied. In July 2014, UniStrip brought a lawsuit against LifeScan in the United States District Court for the Eastern District of Pennsylvania, alleging antitrust violations relating to marketing practices for LifeScan strips. In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that all of Cordis's sales of the CYPHER ™ and CYPHER SELECT ™ Stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Medinol is seeking damages and attorney's fees. After trial in January 2014, the District Court dismissed the case, finding Medinol unreasonably delayed bringing its claims, and Medinol did not appeal the decision. In September 2014, the District Court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol's appeal of this decision has been dismissed. Medinol has filed a petition for review with the United States Supreme Court. Following the divestiture of Cordis, the Company retains any liability that may result from this case. Pharmaceutical Johnson & Johnson acquired the prostate cancer business of Aragon Pharmaceuticals, Inc. (Aragon), including ARN-509, a compound being tested for treatment of prostate cancer, in September 2013. Prior to the acquisition, in May 2011, Medivation, Inc. (Medivation) had sued Aragon and the University of California seeking rights to ARN-509. In December 2012, the state court granted summary judgment to Aragon on Medivation's claims, awarding the rights of the ARN-509 compound to Aragon, and in January 2013, the Court dismissed the case against Aragon. Medivation appealed, and in September 2016, the Court of Appeals affirmed the lower court's ruling in all respects. In April 2016, Morphosys AG, a German biotech company, filed a patent infringement lawsuit against Janssen Biotech, Inc. (JBI), Genmab U.S. Inc. and Genmab A/S (collectively, Genmab) in the United States District Court for the District of Delaware, alleging that JBI’s manufacture and sale of DARZALEX ® (daratumumab) willfully infringes its U.S. Patent No. 8,263,746. Morphosys is seeking money damages. JBI licenses patents and the commercial rights to DARZALEX ® from Genmab. In June 2016, JBI filed a motion to dismiss the lawsuit. REMICADE ® Related Cases U.S. Proceedings In September 2013, Janssen Biotech, Inc. (JBI) and NYU Langone Medical Center (NYU) received an Office Action from the United States Patent and Trademark Office (USPTO) rejecting the claims in U.S. Patent No. 6,284,471 relating to REMICADE ® (infliximab) (the '471 patent) in a reexamination proceeding instituted by a third party. The '471 patent is co-owned by JBI and NYU, and NYU granted JBI an exclusive license to NYU’s rights under the patent. The '471 patent in the United States expires in September 2018. Following several office actions by the patent examiner, including two further rejections, and responses by JBI, the USPTO issued a further action maintaining its rejection of the '471 patent. In May 2015, JBI filed a notice of appeal to the USPTO's Patent Trial and Appeal Board, and the appeal is currently pending. In August 2014, Celltrion Healthcare Co. Ltd. and Celltrion Inc. (together, Celltrion) filed an application with the U.S. Food and Drug Administration (FDA) for approval to make and sell its own infliximab biosimilar. In March 2015, JBI filed a lawsuit in the United States District Court for the District of Massachusetts against Celltrion and Hospira Healthcare Corporation (Hospira), which has exclusive U.S. marketing rights for Celltrion's infliximab biosimilar, seeking, among other things, a declaratory judgment that their biosimilar product infringes or potentially infringes several JBI patents, including the '471 patent and U.S. Patent No. 7,598,083 (the '083 patent). In August 2016, the District Court granted both Celltrion's and Hospira's motions for summary judgment of invalidity of the '471 patent. JBI has appealed those decisions. In June 2016, JBI filed two additional patent infringement lawsuits asserting the '083 patent, one against Celltrion in the United States District Court for the District of Massachusetts and the other against HyClone Laboratories, Inc., the manufacturer of the cell culture media that Celltrion uses to make its biosimilar product, in the United States District Court for the District of Utah. Although the '083 patent is already asserted in the existing lawsuit against Celltrion, the additional lawsuit against Celltrion expands the claims to include any use of the cell culture media made in the United States to manufacture Celltrion's biosimilar. This additional lawsuit against Celltrion has been consolidated with the existing lawsuit discussed above. Trial of the Celltrion lawsuit relating to the '083 patent is scheduled to begin in February 2017. Celltrion has moved to dismiss all counts of the lawsuit related to the '083 patent. The FDA approved Celltrion’s infliximab biosimilar for sale in the United States in April 2016, and the 180-day period for notice of launch of a biosimilar product under the Biologics Price Competition and Innovation Act has passed. Hospira's parent company, Pfizer Inc., has announced its plan to begin shipment of Celltrion's infliximab biosimilar to wholesalers in the United States in late November 2016. Introduction to the U.S. market of the biosimilar will result in a reduction in U.S. sales of REMICADE ® . Canadian Proceedings In March 2013, Hospira filed an impeachment proceeding against The Kennedy Institute of Rheumatology (Kennedy) challenging the validity of a Canadian patent related to REMICADE ® (a Feldman patent), which is exclusively licensed to JBI. In October 2013, Kennedy, along with JBI, Janssen Inc. (Janssen) and Cilag GmbH International (both affiliates of JBI), filed a counterclaim for infringement against Celltrion and Hospira. The counterclaim alleges that the products described in Celltrion’s and Hospira’s marketing applications to Health Canada for their subsequent entry biologics (SEB) to REMICADE ® would infringe the Feldman patents owned by Kennedy. A trial in the patent action concluded in October 2016, and closing arguments are scheduled for January 2017. In January 2014, Health Canada approved Celltrion’s SEB to REMICADE ® , allowing Celltrion to market its infliximab biosimilar in Canada, regardless of the pending patent action. In June 2014, Health Canada approved Hospira’s SEB to REMICADE ® . In July 2014, Janssen filed a lawsuit to compel the Canadian Minister of Health to withdraw the Notice of Compliance for Hospira’s SEB because Hospira did not serve a Notice of Allegation on Janssen to address the patent listed by Janssen on the Patent Register. In March 2015, the parties entered into a settlement agreement whereby Health Canada agreed to a Consent Judgment setting aside Hospira’s Notice of Compliance, subject to Health Canada's appeal, which was filed in June 2015. Nevertheless, Hospira began marketing an infliximab biosimilar as a distributor under Celltrion's Notice of Compliance. In October 2016, the appeals court reversed the Consent Judgment. Hospira continues to market and sell its infliximab biosimilar in Canada. In Canada, if any of the REMICADE ® related patents discussed above is found to be invalid following all appeals, such patent could not be relied upon to prevent the further introduction of infliximab biosimilars. Litigation Against Filers of Abbreviated New Drug Applications (ANDAs) The following summarizes lawsuits pending against generic companies that have filed Abbreviated New Drug Applications (ANDAs) with the FDA, or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson & Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement, invalidity and unenforceability of the applicable patents. In the event the subsidiaries are not successful in these actions, or the statutory 30-month stays of the ANDAs expire before the United States District Court rulings are obtained, the third-party companies involved will have the ability, upon approval of the FDA, to introduce generic versions of the products at issue to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, subsidiaries may settle these actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. CONCERTA ® In December 2014, Janssen Inc. and ALZA Corporation filed a Notice of Application against Actavis Pharma Company (Actavis) in response to Actavis’ Notice of Allegation seeking approval to market a generic version of CONCERTA ® before the expiration of Canadian Patent No. 2,264,852 (the ‘852 patent). The hearing was held in September 2016 and the parties are awaiting a decision. Janssen and ALZA are seeking an order enjoining Actavis from marketing its generic version of CONCERTA ® before the expiration of the ‘852 patent. In October 2016, ALZA Corporation and Janssen Pharmaceuticals, Inc. filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals LLC in response to Amneal’s ANDA seeking approval to market a generic version of CONCERTA ® before the expiration of United States Patent Nos. 8,163,798 and 9,144,549. ZYTIGA ® In June and July 2015, Janssen Biotech, Inc. (JBI) received notices of paragraph IV certification from several companies advising of their respective ANDAs seeking approval for a generic version of ZYTIGA ® before the expiration of one or more patents relating to ZYTIGA ® . In July 2015, JBI, Janssen Oncology, Inc. (Janssen Oncology) and Janssen Research & Development, LLC (collectively, Janssen) and BTG International Ltd. (BTG) filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against several generic ANDA applicants (and certain of their affiliates and/or suppliers) in response to their respective ANDAs seeking approval to market a generic version of ZYTIGA ® before the expiration of United States Patent Nos. 5,604,213 (the '213 patent) and/or 8,822,438 (the '438 patent). The generic companies include Actavis Laboratories, FL, Inc. (Actavis); Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal); Apotex Inc. and Apotex Corp. (collectively, Apotex); Citron Pharma LLC (Citron); Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, Dr. Reddy's); Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan); Par Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. (collectively, Par); Sun Pharmaceutical Industries Ltd. and Sun Pharmaceuticals Industries, Inc. (collectively, Sun); Teva Pharmaceuticals USA, Inc. (Teva); Wockhardt Bio A.G.; Wockhardt USA LLC and Wockhardt Ltd. (collectively, Wockhardt); West-Ward Pharmaceutical Corp. (West-Ward); and Hikma Pharmaceuticals, LLC (Hikma). The Court entered a stay of the lawsuit against Par and Citron, as each agreed to be bound by the decision against the other defendants in the action. In February 2016, the Court set a trial date of October 2017. In August 2016, Janssen and BTG dismissed the ‘213 patent claim against Actavis, the only challenger to the ‘213 patent, based on Actavis’ agreement not to challenge the patent, which expires in December 2016. In August 2015, Janssen and BTG filed an additional jurisdictional protective lawsuit against the Mylan defendants in the United States District Court for the Northern District of West Virginia, which has been stayed. In August 2015, Janssen received a notice of paragraph IV certification from Hetero USA Inc., the U.S. Regulatory Agent for Hetero Labs Limited Unit-V, a division of Hetero Labs Limited (collectively, Hetero) advising of Hetero’s ANDA seeking approval for a generic version of ZYTIGA ® before expiration of the '438 patent. In September 2015, Janssen and BTG filed an amended complaint in the New Jersey lawsuit to allege infringement of the '438 patent by Hetero. In March 2016, Janssen filed a motion to correct inventorship of the ‘438 patent to add an inventor and requested that, should the Court order the requested correction, it grant Janssen leave to amend the complaint to recognize BTG as a co-owner of the ‘438 patent and a co-plaintiff with Janssen with regard to the ‘438 patent infringement claims. In March 2016, Janssen received a notice from Amerigen Pharmaceuticals Limited (Amerigen) advising of Amerigen’s ANDA seeking approval for a generic version of ZYTIGA ® before expiration of the ‘438 patent. In response, Janssen and BTG filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Amerigen in May 2016. In May 2016, Janssen received a notice of paragraph IV certification from Glenmark Pharmaceuticals Inc., on behalf of Glenmark Pharmaceuticals SA, a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (collectively, Glenmark) advising of Glenmark’s ANDA seeking approval for a generic version of ZYTIGA ® before expiration of the ‘438 patent. In response, in June 2016, Janssen and BTG filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Glenmark. The parties have stipulated to a dismissal of Glenmark Pharmaceuticals Ltd. The filing of the above-referenced lawsuits triggered a stay until October 2018 during which the FDA will not grant final approval of the generics' ANDAs unless there is an earlier District Court decision finding the patents-in-suit invalid or not infringed. In each of the above lawsuits, Janssen is seeking an order enjoining the defendants from marketing their generic versions of ZYTIGA ® before the expiration of the relevant patents. In December 2015, Amerigen filed a petition for an Inter Partes Review in the USPTO seeking to invalidate the '438 patent. In May 2016, the USPTO granted the Inter Partes Review, and a decision as to the validity of the ‘438 patent is expected by May 2017. In June 2016, Argentum Pharmaceuticals LLC and Mylan Pharmaceuticals Inc. filed petitions for Inter Partes Review in the USPTO seeking to invalidate the '438 patent and moved to join the Inter Partes Review filed by Amerigen. The USPTO granted Argentum’s motion for joinder, but deferred a decision on Mylan’s motion. In August 2016, Wockhardt Bio AG filed a petition for Inter Partes Review in the USPTO seeking to invalidate the ‘438 patent. COMPLERA ® In August and September 2015, Janssen Pharmaceutica NV and Janssen Sciences Ireland UC (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) filed patent infringement lawsuits in the United States District Courts for the District of Delaware and the District of West Virginia, respectively, against Mylan, Inc. and Mylan Pharmaceuticals, Inc. (collectively, Mylan) in response to Mylan’s ANDA seeking approval to market a generic version of COMPLERA ® before the expiration of United States Patent Nos. 8,841,310 (the '310 patent), 7,125,879 (the '879 patent) and 8,101,629 (the '629 patent). In the West Virginia action, in September 2015, Mylan filed an answer and counterclaims asserting invalidity and non-infringement of the '310 patent, '879 patent, and '629 patent, as well as United States Patent No. 8,080,551 (the ‘551 patent). In March 2016, the District of West Virginia Court stayed th

Restructuring

Restructuring	9 Months Ended
	Oct. 02, 2016
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING The Company announced restructuring actions in its Medical Devices segment to better serve the needs of patients and customers in today’s evolving healthcare marketplace. The Company is undertaking actions to strengthen its go-to-market model, accelerate the pace of innovation, further prioritize key platforms and geographies, and streamline operations while maintaining high quality standards. The Company estimates that, in connection with its plans, it will record pre-tax restructuring and other charges of approximately $2.0 billion to $2.4 billion . In the fiscal third quarter of 2016, the Company recorded a pre-tax charge of $109 million , of which $3 million was included in cost of products sold and $44 million was included in other (income) expense. In the fiscal nine months of 2016, the Company recorded a pre-tax charge of $387 million , of which $27 million was included in cost of products sold and $64 million was included in other (income) expense. See table below for additional details. Total project costs of $977 million have been recorded since the restructuring has been announced. Additionally, as part of the plan, the Company expects that the restructuring actions will result in position eliminations of approximately 4 to 6 percent of the Medical Devices segment’s global workforce over the next two years, subject to any consultation procedures in countries, where required. Approximately 1,170 positions have been eliminated since the restructuring has been announced. The Company estimates that approximately one half of the cumulative pre-tax costs will result in cash outlays, including approximately $500 million of employee severance. Approximately one half of the cumulative pre-tax costs are non-cash, relating primarily to facility rationalization, inventory write-offs and intangible asset write-offs. The following table summarizes the severance related reserves and the associated spending under this initiative through the fiscal nine months of 2016: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, January 3, 2016 $ 484 — 17 501 Current year activity: Charges — 158 229 387 Cash payments (81 ) — (245 ) (326 ) Settled non cash — (158 ) — (158 ) Reserve balance, October 2, 2016* $ 403 — 1 404 *Cash outlays for severance are expected to be substantially paid out over the next 24 months in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses.

Fair Value Measurements (Polici

Fair Value Measurements (Policies)	9 Months Ended
	Oct. 02, 2016
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available for current operations and are classified as current marketable securities.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Oct. 02, 2016
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) October 2, 2016 January 3, 2016 Raw materials and supplies $ 974 936 Goods in process 1,859 2,241 Finished goods 5,655 4,876 Total inventories $ 8,488 8,053

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Oct. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) October 2, 2016 January 3, 2016 Intangible assets with definite lives: Patents and trademarks — gross $ 10,815 8,299 Less accumulated amortization 5,017 4,745 Patents and trademarks — net 5,798 3,554 Customer relationships and other intangibles — gross 17,830 17,583 Less accumulated amortization 6,411 5,816 Customer relationships and other intangibles — net 11,419 11,767 Intangible assets with indefinite lives: Trademarks 7,042 7,023 Purchased in-process research and development 3,383 3,420 Total intangible assets with indefinite lives 10,425 10,443 Total intangible assets — net $ 27,642 25,764
Goodwill	Goodwill as of October 2, 2016 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill, net at January 3, 2016 $ 7,240 2,889 11,500 21,629 Goodwill, related to acquisitions 1,332 — 180 1,512 Goodwill, related to divestitures (24 ) (10 ) — (34 ) Currency translation/Other 27 15 22 64 Goodwill, net at October 2, 2016 $ 8,575 2,894 11,702 23,171

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 02, 2016
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal third quarters in 2016 and 2015 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Third Quarters Ended Cash Flow Hedges By Income Statement Caption October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 Sales to customers (3) $ (12 ) 3 (8 ) (24 ) (1 ) (3 ) Cost of products sold (3) (4 ) 222 13 (34 ) (4 ) 1 Research and development expense (3) (5 ) (10 ) (2 ) 7 1 — Interest (income)/Interest expense, net (4) 29 (13 ) 12 1 — — Other (income) expense, net (3) (5) (4 ) (42 ) (12 ) 12 — (1 ) Total $ 4 160 3 (38 ) (4 ) (3 ) The following table is a summary of the activity related to derivatives designated as cash flow hedges for the fiscal nine months in 2016 and 2015 : Gain/(Loss) Recognized In Accumulated OCI (1) Gain/(Loss) Reclassified From Accumulated OCI Into Income (1) Gain/(Loss) Recognized In Other Income/Expense (2) (Dollars in Millions) Fiscal Nine Months Ended Cash Flow Hedges By Income Statement Caption October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 Sales to customers (3) $ (39 ) (52 ) (29 ) (95 ) (1 ) (5 ) Cost of products sold (3) (226 ) 106 5 82 (10 ) 15 Research and development expense (3) (100 ) (13 ) (98 ) (2 ) — — Interest (income)/Interest expense, net (4) 38 (42 ) 27 (2 ) — — Other (income) expense, net (3) (5) (110 ) 27 (14 ) 54 (3 ) — Total $ (437 ) 26 (109 ) 37 (14 ) 10 All amounts shown in the table above are net of tax. (1) Effective portion (2) Ineffective portion (3) Forward foreign exchange contracts (4) Cross currency interest rate swaps (5) Includes equity collar contracts
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of October 2, 2016 and January 3, 2016 were as follows: October 2, 2016 January 3, 2016 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts (7) $ — 222 — 222 452 Interest rate contracts (2)(4)(7) — 50 — 50 28 Total — 272 — 272 480 Liabilities: Forward foreign exchange contracts (8) — 542 — 542 358 Interest rate contracts (3)(4)(8) — 309 — 309 241 Equity collar contracts (8)(9) — 95 — 95 — Total — 946 — 946 599 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts (7) — 14 — 14 33 Liabilities: Forward foreign exchange contracts (8) — 33 — 33 41 Available For Sale Other Investments: Equity investments (5) 1,332 — — 1,332 1,494 Debt securities (6) $ — 12,237 — 12,237 8,316 (1) 2015 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,494 million , which are classified as Level 1. (2) Includes $35 million and $20 million of non-current other assets for October 2, 2016 and January 3, 2016, respectively. (3) Includes $309 million and $239 million of non-current other liabilities for October 2, 2016 and January 3, 2016, respectively. (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets with the exception of $345 million of current other assets for October 2, 2016 . The carrying amount of the equity investments were $544 million and $528 million as of October 2, 2016 and January 3, 2016, respectively. The unrealized gains were $802 million and $979 million as of October 2, 2016 and January 3, 2016, respectively. The unrealized losses were $14 million and $13 million as of October 2, 2016 and January 3, 2016, respectively. (6) Classified as current marketable securities. (7) Classified as other current assets. (8) Classified as accounts payable. (9) Includes $16 million of non-current other liabilities for October 2, 2016 .
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of October 2, 2016 comprised: October 2, 2016 (Dollars in Millions) Carrying Amount Unrecognized Gain Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 1,971 — — 1,971 1,971 U.S. Gov't Securities (1) 10,498 1 — 10,499 6,997 3,501 Other Sovereign Securities (1) 3,385 — — 3,385 952 2,433 U.S. Reverse repurchase agreements (1) 5,883 — — 5,883 4,882 1,001 Other Reverse repurchase agreements (1) 96 — — 96 96 Corporate debt securities (1) 3,501 1 — 3,502 790 2,711 Money market funds 1,448 — — 1,448 1,448 Time deposits (1) 1,069 — — 1,069 1,069 Subtotal 27,851 2 — 27,853 18,205 9,646 Unrealized Gain Unrealized Loss Gov't securities 10,235 120 (1 ) 10,354 — 10,354 Other Sovereign Securities 91 — — 91 — 91 Corporate debt securities 1,782 11 (1 ) 1,792 — 1,792 Equity investments 50 314 (19 ) 345 — 345 Subtotal Available for Sale (2) $ 12,158 445 (21 ) 12,582 — 12,582 Total cash, cash equivalents and current marketable securities 18,205 22,228 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities at October 2, 2016 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 475 475 Due after one year through five years 11,445 11,575 Due after five years through ten years 188 187 Total debt securities $ 12,108 12,237
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October 2, 2016 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 3,443 3,443 Non-Current Debt 1.125% Notes due 2017 703 705 5.15% Debentures due 2018 899 958 1.65% Notes due 2018 608 616 4.75% Notes due 2019 (1B Euro 1.1198) 1,115 1,287 1.875% Notes due 2019 511 524 0.89% Notes due 2019 299 300 1.125% Notes due 2019 699 700 3% Zero Coupon Convertible Subordinated Debentures due in 2020 94 152 2.95% Debentures due 2020 545 578 3.55% Notes due 2021 447 491 2.45% Notes due 2021 349 367 1.65% Notes due 2021 997 1,013 0.250% Notes due 2022 (1B Euro 1.1198) 1,116 1,132 6.73% Debentures due 2023 249 335 3.375% Notes due 2023 807 875 2.05% Notes due 2023 497 507 0.650% Notes due 2024 (750MM Euro 1.1198) 834 863 5.50% Notes due 2024 (500 MM GBP 1.3000) 643 868 2.45% Notes due 2026 1,989 2,059 1.150% Notes due 2028 (750MM Euro 1.1198) 830 886 6.95% Notes due 2029 296 440 4.95% Debentures due 2033 497 635 4.375% Notes due 2033 857 1,026 1.650% Notes due 2035 (1.5B Euro 1.1198) 1,660 1,884 3.55% Notes due 2036 987 1,098 5.95% Notes due 2037 991 1,457 5.85% Debentures due 2038 695 1,016 4.50% Debentures due 2040 537 674 4.85% Notes due 2041 296 390 4.50% Notes due 2043 495 624 3.70% Notes due 2046 1,970 2,213 Other 34 34 Total Non-Current Debt $ 23,546 26,707

Pensions and Other Postretire24

Pensions and Other Postretirement Benefits (Tables)	9 Months Ended
	Oct. 02, 2016
Compensation and Retirement Disclosure [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit cost for the Company’s defined benefit retirement plans and other benefit plans for the fiscal third quarters of 2016 and 2015 include the following components: Fiscal Third Quarters Ended Retirement Plans Other Benefit Plans (Dollars in Millions) October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 Service cost $ 224 247 56 64 Interest cost 232 246 39 46 Expected return on plan assets (490 ) (451 ) (1 ) (2 ) Amortization of prior service cost/(credit) 2 — (9 ) (8 ) Recognized actuarial losses 123 186 33 50 Curtailments and settlements 6 — — — Net periodic benefit cost $ 97 228 118 150 Fiscal Nine Months Ended Retirement Plans Other Benefit Plans (Dollars in Millions) October 2, 2016 September 27, 2015 October 2, 2016 September 27, 2015 Service cost $ 676 744 166 193 Interest cost 698 743 118 139 Expected return on plan assets (1,475 ) (1,361 ) (4 ) (5 ) Amortization of prior service cost/(credit) 2 1 (25 ) (25 ) Recognized actuarial losses 371 560 101 150 Curtailments and settlements 11 4 — — Net periodic benefit cost $ 283 691 356 452

Accumulated Other Comprehensi25

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Oct. 02, 2016
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) January 3, 2016 $ (8,435 ) 604 (5,298 ) (36 ) (13,165 ) Net change 490 (7 ) 295 (328 ) 450 October 2, 2016 $ (7,945 ) 597 (5,003 ) (364 ) (12,715 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Oct. 02, 2016
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal third quarters ended October 2, 2016 and September 27, 2015 : Fiscal Third Quarters Ended (Shares in Millions) October 2, 2016 September 27, 2015 Basic net earnings per share $ 1.56 1.21 Average shares outstanding — basic 2,731.6 2,768.4 Potential shares exercisable under stock option plans 140.8 129.4 Less: shares which could be repurchased under treasury stock method (88.4 ) (92.8 ) Convertible debt shares 1.4 2.2 Average shares outstanding — diluted 2,785.4 2,807.2 Diluted net earnings per share $ 1.53 1.20 The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal nine months ended October 2, 2016 and September 27, 2015 : Fiscal Nine Months Ended (Shares in Millions) October 2, 2016 September 27, 2015 Basic net earnings per share $ 4.64 4.39 Average shares outstanding — basic 2,744.9 2,774.8 Potential shares exercisable under stock option plans 144.0 129.1 Less: shares which could be repurchased under treasury stock method (93.7 ) (89.0 ) Convertible debt shares 1.4 2.2 Average shares outstanding — diluted 2,796.6 2,817.1 Diluted net earnings per share $ 4.55 4.33

Segments of Business and Geog27

Segments of Business and Geographic Areas (Tables)	9 Months Ended
	Oct. 02, 2016
Segment Reporting [Abstract]
Sales By Segment Of Business	Fiscal Third Quarters Ended (Dollars in Millions) October 2, September 27, Percent Change Consumer United States $ 1,291 1,277 1.1 % International 1,970 2,037 (3.3 ) Total 3,261 3,314 (1.6 ) Pharmaceutical United States 5,042 4,509 11.8 International 3,358 3,185 5.4 Total 8,400 7,694 9.2 Medical Devices United States 3,048 3,005 1.4 International 3,111 3,089 0.7 Total 6,159 6,094 1.1 Worldwide United States 9,381 8,791 6.7 International 8,439 8,311 1.5 Total $ 17,820 17,102 4.2 % Fiscal Nine Months Ended (Dollars in Millions) October 2, September 27, Percent Change Consumer United States $ 4,033 3,991 1.1 % International 5,842 6,196 (5.7 ) Total 9,875 10,187 (3.1 ) Pharmaceutical United States 15,123 13,423 12.7 International 10,109 9,943 1.7 Total 25,232 23,366 8.0 Medical Devices United States 9,118 8,980 1.5 International 9,559 9,730 (1.8 ) Total 18,677 18,710 (0.2 ) Worldwide United States 28,274 26,394 7.1 International 25,510 25,869 (1.4 ) Total $ 53,784 52,263 2.9 %
Operating Profit by Segment of Business	Fiscal Third Quarters Ended (Dollars in Millions) October 2, September 27, Percent Change Consumer (1) $ 679 811 (16.3 )% Pharmaceutical (2) 3,309 2,732 21.1 Medical Devices (3) 1,526 835 82.8 Segments operating profit 5,514 4,378 25.9 Less: Expense not allocated to segments (4) 233 256 Worldwide income before tax $ 5,281 4,122 28.1 % Fiscal Nine Months Ended (Dollars in Millions) October 2, 2016 September 27, 2015 Percent Change Consumer (1) $ 1,816 1,772 2.5 % Pharmaceutical (2) 10,340 9,816 5.3 Medical Devices (3) 4,041 4,640 (12.9 ) Segments operating profit 16,197 16,228 (0.2 ) Less: Expense not allocated to segments (4) 718 790 Worldwide income before taxes $ 15,479 15,438 0.3 % (1) Includes a gain of $229 million from the divestiture of the SPLENDA ® brand recorded in the fiscal third quarter and fiscal nine months of 2015. (2) Includes litigation expense of $136 million recorded in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA ® (tapentadol), NUCYNTA ® ER (tapentadol extended-release tablets), and NUCYNTA ® (tapentadol) oral solution. Includes a positive adjustment of $513 million and $462 million to previous reserve estimates in the fiscal nine months of 2016 and 2015, respectively. (3) Includes a restructuring related charge of $109 million and $387 million in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $55 million and $731 million recorded in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $409 million in the fiscal third quarter of 2015. Includes a $346 million intangible asset write-down related to Acclarent recorded in the fiscal third quarter and fiscal nine months of 2015. The fiscal nine months of 2015 included $148 million for costs associated with the DePuy ASR TM Hip program. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	Fiscal Third Quarters Ended (Dollars in Millions) October 2, 2016 September 27, 2015 Percent Change United States $ 9,381 8,791 6.7 % Europe 3,832 3,802 0.8 Western Hemisphere, excluding U.S. 1,396 1,463 (4.6 ) Asia-Pacific, Africa 3,211 3,046 5.4 Total $ 17,820 17,102 4.2 % Fiscal Nine Months Ended (Dollars in Millions) October 2, 2016 September 27, 2015 Percent Change United States $ 28,274 26,394 7.1 % Europe 11,769 11,993 (1.9 ) Western Hemisphere, excluding U.S. 4,269 4,603 (7.3 ) Asia-Pacific, Africa 9,472 9,273 2.1 Total $ 53,784 52,263 2.9 %

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Oct. 02, 2016
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated spending under this initiative through the fiscal nine months of 2016: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, January 3, 2016 $ 484 — 17 501 Current year activity: Charges — 158 229 387 Cash payments (81 ) — (245 ) (326 ) Settled non cash — (158 ) — (158 ) Reserve balance, October 2, 2016* $ 403 — 1 404 *Cash outlays for severance are expected to be substantially paid out over the next 24 months in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses.

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Oct. 02, 2016	Oct. 02, 2016	Sep. 27, 2015
Tax benefit	$ 47	$ 335
Net Cash Provided by (Used in) Operating Activities		12,114	$ 14,484
Net Cash Provided by (Used in) Financing Activities		(5,087)	(7,842)
New Accounting Pronouncement, Early Adoption, Effect | Accounting Standards Update 2016-09, Statutory Tax Withholding Component
Net Cash Provided by (Used in) Operating Activities		264	287
Net Cash Provided by (Used in) Financing Activities		$ (264)	$ (287)

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Oct. 02, 2016	Jan. 03, 2016
Summary of Inventories
Raw materials and supplies	$ 974	$ 936
Goods in process	1,859	2,241
Finished goods	5,655	4,876
Total inventories	$ 8,488	$ 8,053

Intangible Assets and Goodwil31

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	Oct. 02, 2016	Jan. 03, 2016
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	$ 10,425	$ 10,443
Total intangible assets - net	27,642	25,764
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	7,042	7,023
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	3,383	3,420
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	10,815	8,299
Less accumulated amortization	5,017	4,745
Finite-Lived Intangible Assets, Net	5,798	3,554
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	17,830	17,583
Less accumulated amortization	6,411	5,816
Finite-Lived Intangible Assets, Net	$ 11,419	$ 11,767

Goodwill By Segment (Details)

Goodwill By Segment (Details) $ in Millions	9 Months Ended
	Oct. 02, 2016USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 21,629
Goodwill, related to acquisitions	1,512
Goodwill, related to divestitures	(34)
Currency translation/Other	64
Goodwill End of Period	23,171
Consumer
Goodwill [Roll Forward]
Goodwill Beginning of Period	7,240
Goodwill, related to acquisitions	1,332
Goodwill, related to divestitures	(24)
Currency translation/Other	27
Goodwill End of Period	8,575
Pharmaceutical
Goodwill [Roll Forward]
Goodwill Beginning of Period	2,889
Goodwill, related to acquisitions	0
Goodwill, related to divestitures	(10)
Currency translation/Other	15
Goodwill End of Period	2,894
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	11,500
Goodwill, related to acquisitions	180
Goodwill, related to divestitures	0
Currency translation/Other	22
Goodwill End of Period	$ 11,702

Intangible Assets and Goodwil33

Intangible Assets and Goodwill (Details Textuals) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Oct. 02, 2016	Oct. 02, 2016	Sep. 27, 2015
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 1,300	$ 1,300
Finite-Lived Intangible Assets, Amortization Expense, Year Two	1,300	1,300
Finite-Lived Intangible Assets, Amortization Expense, Year Three	1,300	1,300
Finite-Lived Intangible Assets, Amortization Expense, Year Four	1,300	1,300
Finite-Lived Intangible Assets, Amortization Expense, Year Five	1,300	1,300
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets		$ 895	$ 912
Finite-lived Intangible Assets Acquired	2,300
Patents And Trademarks
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life		19 years
Customer relationships and other intangible assets
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life		24 years
Vogue International LLC [Member] | Consumer
Intangible Assets and Goodwill (Textuals)
Finite-lived Intangible Assets Acquired	2,300
Business Acquisition, Goodwill, Expected Tax Deductible Amount	$ 1,100	$ 1,100

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015	Jan. 03, 2016
Derivative [Line Items]
Foreign currency translation	$ (94)	$ (1,069)	$ 490	$ (2,729)
Accumulated other comprehensive income on derivatives, after tax	364		$ 364		$ 36
Reclassification of foreign exchange contracts into earnings, period			next 12 months
Maximum length of time for hedge exposure			18 months
Other income/(expense), net, related to foreign exchange contracts, non hedging	$ 35	$ (8)	$ (6)	$ 32
Weighted average interest rate on non-current debt	3.14%		3.14%
Excess of the estimated fair value over the carrying value of debt					$ 1,700
Foreign exchange contracts
Derivative [Line Items]
Derivative notional amounts outstanding	$ 35,000		$ 35,000
Cross currency interest rate swaps
Derivative [Line Items]
Derivative notional amounts outstanding	2,300		2,300
Interest Rate Contract
Derivative [Line Items]
Derivative notional amounts outstanding	2,200		2,200
Equity Contract
Derivative [Line Items]
Derivative notional amounts outstanding	$ 400		400
Other Comprehensive Income (Loss) [Member]
Derivative [Line Items]
Foreign currency translation			$ 76

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - Designated as Hedging Instrument - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1]	$ 4	$ 160	$ (437)	$ 26
Gain/ (Loss) reclassified from Accumulated OCI into income	[1]	3	(38)	(109)	37
Gain/ (Loss) recognized in Other income/expense	[2]	(4)	(3)	(14)	10
Foreign exchange contracts | Sales to customers
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	(12)	3	(39)	(52)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	(8)	(24)	(29)	(95)
Gain/ (Loss) recognized in Other income/expense	[2],[3]	(1)	(3)	(1)	(5)
Foreign exchange contracts | Cost of products sold
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	(4)	222	(226)	106
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	13	(34)	5	82
Gain/ (Loss) recognized in Other income/expense	[2],[3]	(4)	1	(10)	15
Foreign exchange contracts | Research and development expense
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3]	(5)	(10)	(100)	(13)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3]	(2)	7	(98)	(2)
Gain/ (Loss) recognized in Other income/expense	[2],[3]	1	0	0	0
Foreign exchange contracts | Other (income) expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[3],[4]	(4)	(42)	(110)	27
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[3],[4]	(12)	12	(14)	54
Gain/ (Loss) recognized in Other income/expense	[2],[3],[4]	0	(1)	(3)	0
Cross currency interest rate swaps | Interest (income)/Interest expense, net
Summary of designated derivatives
Gain/ (Loss) recognized in Accumulated OCI	[1],[5]	29	(13)	38	(42)
Gain/ (Loss) reclassified from Accumulated OCI into income	[1],[5]	12	1	27	(2)
Gain/ (Loss) recognized in Other income/expense	[2],[5]	$ 0	$ 0	$ 0	$ 0
[1]	Effective portion
[2]	Ineffective portion
[3]	Forward foreign exchange contracts
[4]	Includes equity collar contracts
[5]	Cross currency interest rate swaps

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions		Oct. 02, 2016		Jan. 03, 2016
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		$ 272
Derivatives designated as hedging instruments : Liabilities		946
Available-for-sale Securities, Equity Securities	[1]	1,332		$ 1,494	[2]
Available-for-sale Securities	[3]	12,237		8,316	[2]
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		0
Derivatives designated as hedging instruments : Liabilities		0
Available-for-sale Securities, Equity Securities		1,332	[1]	1,494
Available-for-sale Securities	[3]	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		272		480	[2]
Derivatives designated as hedging instruments : Liabilities		946		599	[2]
Available-for-sale Securities, Equity Securities	[1]	0
Available-for-sale Securities	[3]	12,237
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets		0
Derivatives designated as hedging instruments : Liabilities		0
Available-for-sale Securities, Equity Securities	[1]	0
Available-for-sale Securities	[3]	0
Interest Rate Contract
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount		2,200
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	50
Derivatives designated as hedging instruments : Liabilities	[6],[7],[8]	309
Derivative Assets, Noncurrent		35		20
Derivative Liabilities, Noncurrent		309		239
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	0
Derivatives designated as hedging instruments : Liabilities	[6],[7],[8]	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	50		28	[2]
Derivatives designated as hedging instruments : Liabilities	[6],[7],[8]	309		241	[2]
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4],[5],[6]	0
Derivatives designated as hedging instruments : Liabilities	[6],[7],[8]	0
Equity Contract
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount		400
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	[7],[9]	95
Derivative Liabilities, Noncurrent		16
Equity Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	[7],[9]	0
Equity Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	[7],[9]	95		0	[2]
Equity Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Liabilities	[7],[9]	0
Foreign exchange contracts
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount		35,000
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	222
Derivatives designated as hedging instruments : Liabilities	[7]	542
Derivatives not designated as hedging instruments : Assets	[4]	14
Derivatives not designated as hedging instruments : Liabilities	[7]	33
Foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	0
Derivatives designated as hedging instruments : Liabilities	[7]	0
Derivatives not designated as hedging instruments : Assets	[4]	0
Derivatives not designated as hedging instruments : Liabilities	[7]	0
Foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	222		452	[2]
Derivatives designated as hedging instruments : Liabilities	[7]	542		358	[2]
Derivatives not designated as hedging instruments : Assets	[4]	14		33	[2]
Derivatives not designated as hedging instruments : Liabilities	[7]	33		41	[2]
Foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	[4]	0
Derivatives designated as hedging instruments : Liabilities	[7]	0
Derivatives not designated as hedging instruments : Assets	[4]	0
Derivatives not designated as hedging instruments : Liabilities	[7]	0
Cross Currency Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount		2,300
Equity Securities [Member]
Financial assets and liabilities at fair value
Available-for-sale Securities, Equity Securities		544		528
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		802		979
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		14		$ 13
Other Current Assets [Member] | Equity Securities [Member]
Financial assets and liabilities at fair value
Available-for-sale Securities, Equity Securities		$ 345
[1]	Classified as non-current other assets with the exception of $345 million of current other assets for October 2, 2016. The carrying amount of the equity investments were $544 million and $528 million as of October 2, 2016 and January 3, 2016, respectively. The unrealized gains were $802 million and $979 million as of October 2, 2016 and January 3, 2016, respectively. The unrealized losses were $14 million and $13 million as of October 2, 2016 and January 3, 2016, respectively
[2]	2015 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,494 million, which are classified as Level 1.
[3]	Classified as current marketable securities
[4]	Classified as other current assets
[5]	Includes $35 million and $20 million of non-current other assets for October 2, 2016 and January 3, 2016, respectively.
[6]	Includes cross currency interest rate swaps and interest rate swaps.
[7]	Classified as accounts payable.
[8]	Includes $309 million and $239 million of non-current other liabilities for October 2, 2016 and January 3, 2016, respectively.
[9]	Includes $16 million of non-current other liabilities for October 2, 2016.

Fair Value Measurements - Cash

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions		Oct. 02, 2016	Jan. 03, 2016		Sep. 27, 2015	Dec. 28, 2014
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Estimated Fair Value	[1]	$ 12,237	$ 8,316	[2]
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		18,205	13,732		$ 13,639	$ 14,523
Marketable securities		22,228	$ 24,644
Held-to-maturity Securities
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount		27,851
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		2
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value		27,853
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		18,205
Marketable securities		9,646
Held-to-maturity Securities | Cash
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount		1,971
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value		1,971
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		1,971
Held-to-maturity Securities | U.S. Gov't Securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	10,498
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		1
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	10,499
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	6,997
Marketable securities	[3]	3,501
Held-to-maturity Securities | Other Sovereign Securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	3,385
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	3,385
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	952
Marketable securities	[3]	2,433
Held-to-maturity Securities | U.S. Reverse repurchase agreements(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	5,883
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	5,883
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	4,882
Marketable securities	[3]	1,001
Held-to-maturity Securities | Other Reverse repurchase agreements(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	96
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	96
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	96
Held-to-maturity Securities | Corporate debt securities(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	3,501
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		1
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	3,502
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	790
Marketable securities	[3]	2,711
Held-to-maturity Securities | Money market funds
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount		1,448
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value		1,448
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		1,448
Held-to-maturity Securities | Time deposits(1)
Held-to-maturity Securities [Abstract]
Held-to-maturity Securities - Carrying Amount	[3]	1,069
Held-to-maturity Securities, Accumulated Unrecognized Holding Gain		0
Held-to-maturity Securities, Accumulated Unrecognized Holding Loss		0
Held-to-maturity Securities - Estimated Fair Value	[3]	1,069
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[3]	1,069
Available-for-sale Securities
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[4]	12,158
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[4]	445
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[4]	(21)
Available-for-sale Securities - Estimated Fair Value	[4]	12,582
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents	[4]	0
Marketable securities	[4]	12,582
Available-for-sale Securities | U.S. Gov't Securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[4]	10,235
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[4]	120
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[4]	(1)
Available-for-sale Securities - Estimated Fair Value	[4]	10,354
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		0
Marketable securities	[4]	10,354
Available-for-sale Securities | Other Sovereign Securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[4]	91
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[4]	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[4]	0
Available-for-sale Securities - Estimated Fair Value	[4]	91
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		0
Marketable securities	[4]	91
Available-for-sale Securities | Corporate debt securities(1)
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[4]	1,782
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[4]	11
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[4]	(1)
Available-for-sale Securities - Estimated Fair Value	[4]	1,792
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		0
Marketable securities	[4]	1,792
Available-for-sale Securities | Equity investments
Available-for-sale Securities [Abstract]
Available-for-sale Securities - Carrying Amount	[4]	50
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[4]	314
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[4]	(19)
Available-for-sale Securities - Estimated Fair Value	[4]	345
Available-for-sale Securities and Held-to-maturity Securities [Abstract]
Cash and Cash Equivalents		0
Marketable securities	[4]	$ 345
[1]	Classified as current marketable securities
[2]	2015 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,494 million, which are classified as Level 1.
[3]	Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings
[4]	Available for sale securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.

Fair Value Measurements - Sche

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Oct. 02, 2016USD ($)
Cost Basis
Due within one year	$ 475
Due after one year through five years	11,445
Due after five years through ten years	188
Total debt securities	12,108	[1]
Fair Value
Due within one year	475
Due after one year through five years	11,575
Due after five years through ten years	187
Total debt securities	$ 12,237	[1]
[1]	Classified as current marketable securities

Fair Value Measurements - Fin39

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($) $ in Millions	Oct. 02, 2016	Jan. 03, 2016
Financial Liabilities
Current Debt	$ 3,443	$ 7,004
Non-Current Debt
Non-Current Debt	23,546	$ 12,857
Carrying Amount
Financial Liabilities
Current Debt	3,443
Non-Current Debt
Non-Current Debt	23,546
Estimated Fair Value
Financial Liabilities
Current Debt	3,443
Non-Current Debt
Non-Current Debt	$ 26,707
1.125% Notes due 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.125%
1.125% Notes due 2017 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 703
1.125% Notes due 2017 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 705
5.15% Debentures due 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.15%
5.15% Debentures due 2018 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 899
5.15% Debentures due 2018 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 958
1.65% Notes due 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.65%
1.65% Notes due 2018 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 608
1.65% Notes due 2018 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 616
4.75% Notes due 2019 (1B Euro 1.1198)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.75%
4.75% Notes due 2019 (1B Euro 1.1198) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,115
4.75% Notes due 2019 (1B Euro 1.1198) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,287
1.875% Notes due 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.875%
1.875% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 511
1.875% Notes due 2019 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 524
0.89% Notes due 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.89%
0.89% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 299
0.89% Notes due 2019 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 300
1.125% Notes due 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.125%
1.125% Notes due 2019 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 699
1.125% Notes due 2019 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 700
3% Zero Coupon Convertible Subordinated Debentures due in 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.00%
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 94
3% Zero Coupon Convertible Subordinated Debentures due in 2020 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 152
2.95% Debentures due 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.95%
2.95% Debentures due 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 545
2.95% Debentures due 2020 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 578
3.55% Notes due 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.55%
3.55% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 447
3.55% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 491
2.45% Notes due 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.45%
2.45% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 349
2.45% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 367
1.65% Notes due 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.65%
1.65% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 997
1.65% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,013
0.250% Notes due 2022 (1B Euro 1.1198)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.25%
0.250% Notes due 2022 (1B Euro 1.1198) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,116
0.250% Notes due 2022 (1B Euro 1.1198) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,132
6.73% Debentures due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 249
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 335
3.375% Notes due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 807
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 875
2.05% Notes due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.05%
2.05% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 497
2.05% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 507
0.650% Notes due 2024 (750MM Euro 1.1198)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.65%
0.650% Notes due 2024 (750MM Euro 1.1198) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 834
0.650% Notes due 2024 (750MM Euro 1.1198) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 863
5.50% Notes due 2024 (500 MM GBP 1.3000)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.50%
5.50% Notes due 2024 (500 MM GBP 1.3000) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 643
5.50% Notes due 2024 (500 MM GBP 1.3000) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 868
2.45% Notes due 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,989
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,059
1.150% Notes due 2028 (750MM Euro 1.1198)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.15%
1.150% Notes due 2028 (750MM Euro 1.1198) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 830
1.150% Notes due 2028 (750MM Euro 1.1198) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 886
6.95% Notes due 2029
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 296
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 440
4.95% Debentures due 2033
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 497
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 635
4.375% Notes due 2033
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 857
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,026
1.650% Notes due 2035 (1.5B Euro 1.1198)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.65%
1.650% Notes due 2035 (1.5B Euro 1.1198) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,660
1.650% Notes due 2035 (1.5B Euro 1.1198) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,884
3.55% Notes due 2036
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 987
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,098
5.95% Notes due 2037
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,457
5.85% Debentures due 2038
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 695
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,016
4.50% Debentures due 2040
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 537
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 674
4.85% Notes due 2041
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 296
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 390
4.50% Notes due 2043
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 495
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 624
3.70% Notes due 2046
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,970
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	2,213
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	34
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 34

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Billions	9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015
Income Tax (Textuals)
Effective Income Tax Rate, Continuing Operations	17.80%	21.00%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	0.80%
Other tax item percent	2.00%
Unrecognized tax benefits	$ 3.1

Pensions and Other Postretire41

Pensions and Other Postretirement Benefits - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 224	$ 247	$ 676	$ 744
Interest cost	232	246	698	743
Expected return on plan assets	(490)	(451)	(1,475)	(1,361)
Amortization of prior service cost/(credit)	2	0	2	1
Recognized actuarial losses	123	186	371	560
Curtailments and settlements	6	0	11	4
Net periodic benefit cost	97	228	283	691
Other Benefit Plans
Components of net periodic benefit cost
Service cost	56	64	166	193
Interest cost	39	46	118	139
Expected return on plan assets	(1)	(2)	(4)	(5)
Amortization of prior service cost/(credit)	(9)	(8)	(25)	(25)
Recognized actuarial losses	33	50	101	150
Curtailments and settlements	0	0	0	0
Net periodic benefit cost	$ 118	$ 150	$ 356	$ 452

Pensions and Other Postretire42

Pensions and Other Postretirement Benefit (Details) $ in Millions	9 Months Ended
	Oct. 02, 2016USD ($)
U.S. retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 372
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 21

Accumulated Other Comprehensi43

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Foreign Currency Translation
Beginning Balance			$ (8,435)
Net change	$ (94)	$ (1,069)	490	$ (2,729)
Ending Balance	(7,945)		(7,945)
Gain /(Loss) on Securities
Beginning Balance			604
Net change	(13)	(90)	(7)	140
Ending Balance	597		597
Employee Benefit Plans
Begining Balance			(5,298)
Net change	98	154	295	461
Ending Balance	(5,003)		(5,003)
Gain/(Loss) on Derivatives & Hedges
Beginning Balance			(36)
Net change	1	198	(328)	(11)
Ending Balance	(364)		(364)
Total Accumulated Other Comprehensive Income (Loss)
Beginning Balance			(13,165)
Net change	(8)	$ (807)	450	$ (2,139)
Ending Balance	$ (12,715)		$ (12,715)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 1.56	$ 1.21	$ 4.64	$ 4.39
Average shares outstanding — basic	2,731,600,000	2,768,400,000	2,744,900,000	2,774,800,000
Potential shares exercisable under stock option plans	140,800,000	129,400,000	144,000,000	129,100,000
Less: shares which could be repurchased under treasury stock method	(88,400,000)	(92,800,000)	(93,700,000)	(89,000,000)
Convertible debt shares	1,400,000	2,200,000	1,400,000	2,200,000
Average shares outstanding — diluted	2,785,400,000	2,807,200,000	2,796,600,000	2,817,100,000
Diluted net earnings per share	$ 1.53	$ 1.20	$ 4.55	$ 4.33
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	20,000,000	0	20,000,000

Segments of Business and Geog45

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Jun. 28, 2015	Oct. 02, 2016	Sep. 27, 2015
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges				$ 276	$ 1,274
Sales by segment of business
Sales	$ 17,820	$ 17,102		$ 53,784	52,263
Percentage Change In Sales By Segment Of Business	4.20%			2.90%
United States
Sales by segment of business
Sales	$ 9,381	8,791		$ 28,274	26,394
Percentage Change In Sales By Segment Of Business	6.70%			7.10%
International
Sales by segment of business
Sales	$ 8,439	8,311		$ 25,510	25,869
Percentage Change In Sales By Segment Of Business	1.50%			(1.40%)
Consumer
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges		229			229
Sales by segment of business
Sales	$ 3,261	3,314		$ 9,875	10,187
Percentage Change In Sales By Segment Of Business	(1.60%)			(3.10%)
Consumer | United States
Sales by segment of business
Sales	$ 1,291	1,277		$ 4,033	3,991
Percentage Change In Sales By Segment Of Business	1.10%			1.10%
Consumer | International
Sales by segment of business
Sales	$ 1,970	2,037		$ 5,842	6,196
Percentage Change In Sales By Segment Of Business	(3.30%)			(5.70%)
Pharmaceutical
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges			$ 981		981
Sales by segment of business
Sales	$ 8,400	7,694		$ 25,232	23,366
Percentage Change In Sales By Segment Of Business	9.20%			8.00%
Pharmaceutical | United States
Sales by segment of business
Sales	$ 5,042	4,509		$ 15,123	13,423
Percentage Change In Sales By Segment Of Business	11.80%			12.70%
Pharmaceutical | International
Sales by segment of business
Sales	$ 3,358	3,185		$ 10,109	9,943
Percentage Change In Sales By Segment Of Business	5.40%			1.70%
Medical Devices
Sales by segment of business
Sales	$ 6,159	6,094		$ 18,677	18,710
Percentage Change In Sales By Segment Of Business	1.10%			(0.20%)
Medical Devices | United States
Sales by segment of business
Sales	$ 3,048	3,005		$ 9,118	8,980
Percentage Change In Sales By Segment Of Business	1.40%			1.50%
Medical Devices | International
Sales by segment of business
Sales	$ 3,111	$ 3,089		$ 9,559	$ 9,730
Percentage Change In Sales By Segment Of Business	0.70%			(1.80%)

Segments of Business and Geog46

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Jun. 28, 2015	Oct. 02, 2016	Sep. 27, 2015
Segment Reporting Information [Line Items]
Percentage Change in Operating Income Loss		28.10%			0.30%
Earnings before provision for taxes on income		$ 5,281	$ 4,122		$ 15,479	$ 15,438
Gain (Loss) on Sale of Assets and Asset Impairment Charges					276	1,274
Asset write-downs					187	367
Restructuring charges		62	0		296	0
Consumer
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges			229			229
Pharmaceutical
Segment Reporting Information [Line Items]
Gain (Loss) on Sale of Assets and Asset Impairment Charges				$ 981		981
Valuation Allowances and Reserves, Adjustments					513	462
Litigation Expense						136
Medical Devices
Segment Reporting Information [Line Items]
Litigation Expense		55	409		731
Asset write-downs			346			346
Restructuring charges		109			387
Litigation Settlement, Amount						0
Product Liability Accrual, Period Expense						148
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income		$ 5,514	4,378		$ 16,197	16,228
Percentage Change in Operating Income Loss		25.90%			(0.20%)
Operating Segments [Member] | Consumer
Segment Reporting Information [Line Items]
Total Segment Operating Income	[1]	$ 679	811		$ 1,816	1,772
Percentage Change in Operating Income Loss		(16.30%)			2.50%
Operating Segments [Member] | Pharmaceutical
Segment Reporting Information [Line Items]
Total Segment Operating Income	[2]	$ 3,309	2,732		$ 10,340	9,816
Percentage Change in Operating Income Loss		21.10%			5.30%
Operating Segments [Member] | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income	[3]	$ 1,526	835		$ 4,041	4,640
Percentage Change in Operating Income Loss		82.80%			(12.90%)
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Total Segment Operating Income	[4]	$ 233	$ 256		$ 718	$ 790
[1]	Includes a gain of $229 million from the divestiture of the SPLENDA® brand recorded in the fiscal third quarter and fiscal nine months of 2015.
[2]	Includes litigation expense of $136 million recorded in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes a positive adjustment of $513 million and $462 million to previous reserve estimates in the fiscal nine months of 2016 and 2015, respectively.
[3]	Includes a restructuring related charge of $109 million and $387 million in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $55 million and $731 million recorded in the fiscal third quarter and fiscal nine months of 2016, respectively. Includes litigation expense of $409 million in the fiscal third quarter of 2015. Includes a $346 million intangible asset write-down related to Acclarent recorded in the fiscal third quarter and fiscal nine months of 2015. The fiscal nine months of 2015 included $148 million for costs associated with the DePuy ASRTM Hip program.
[4]	Amounts not allocated to segments include interest income/expense and general corporate income/expense.

Segments of Business and Geog47

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Sales by geographic area
Sales	$ 17,820	$ 17,102	$ 53,784	$ 52,263
Percentage Change In Sales By Geographic Area	4.20%		2.90%
UNITED STATES
Sales by geographic area
Sales	$ 9,381	8,791	$ 28,274	26,394
Percentage Change In Sales By Geographic Area	6.70%		7.10%
Europe
Sales by geographic area
Sales	$ 3,832	3,802	$ 11,769	11,993
Percentage Change In Sales By Geographic Area	0.80%		(1.90%)
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,396	1,463	$ 4,269	4,603
Percentage Change In Sales By Geographic Area	(4.60%)		(7.30%)
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,211	3,046	$ 9,472	9,273
Percentage Change In Sales By Geographic Area	5.40%		2.10%
Medical Devices [Member]
Sales by geographic area
Sales	$ 6,159	6,094	$ 18,677	18,710
Medical Devices [Member] | UNITED STATES
Sales by geographic area
Sales	$ 3,048	$ 3,005	$ 9,118	$ 8,980

Business Combinations and Div48

Business Combinations and Divestitures (Details) - USD ($) $ in Millions	Jul. 18, 2016	Mar. 31, 2017	Oct. 02, 2016	Jul. 03, 2016	Sep. 27, 2015	Jun. 28, 2015	Oct. 02, 2016	Sep. 27, 2015
Business Acquisition [Line Items]
Payments to acquire businesses							$ 4,050	$ 233
Finite-lived Intangible Assets Acquired			$ 2,300
Proceeds from divestiture							873	1,620
Pre-tax gain on divestiture							276	1,274
API [Member]
Business Acquisition [Line Items]
Proceeds from divestiture				$ 650
Nucynta [Member]
Business Acquisition [Line Items]
Proceeds from sales of business						$ 1,050
Consumer
Business Acquisition [Line Items]
Pre-tax gain on divestiture					$ 229			229
Pharmaceutical
Business Acquisition [Line Items]
Pre-tax gain on divestiture						$ 981		$ 981
Vogue International LLC [Member]
Business Acquisition [Line Items]
Weighted average useful life			22 years
Vogue International LLC [Member] | Consumer
Business Acquisition [Line Items]
Payments to acquire businesses	$ 3,300
Finite-lived Intangible Assets Acquired			$ 2,300
Business Acquisition, Goodwill, Expected Tax Deductible Amount			$ 1,100				$ 1,100
Abbott Medical Optics [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Payments to acquire businesses		$ 4,325
Trademarks | Vogue International LLC [Member]
Business Acquisition [Line Items]
Definite lives			22 years
Trademarks | Minimum [Member] | Vogue International LLC [Member]
Business Acquisition [Line Items]
Definite lives			10 years
Trademarks | Maximum [Member] | Vogue International LLC [Member]
Business Acquisition [Line Items]
Definite lives			22 years
Customer Relationships [Member] | Vogue International LLC [Member]
Business Acquisition [Line Items]
Definite lives			15 years

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	1 Months Ended		3 Months Ended		9 Months Ended
	May 31, 2014	Mar. 31, 2013patents	Oct. 02, 2016USD ($)claimant	Sep. 27, 2015USD ($)	Oct. 02, 2016USD ($)patentsclaimant
ASR
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			2,900		2,900
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			9,300		9,300
Pelvic Meshes
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			53,400		53,400
Risperdal
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			15,400		15,400
Xarelto [Member]
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			15,600		15,600
Baby Powder [Member]
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants			2,400		2,400
settled litigation | misdemeanor violation [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Amount | $					$ 20
settled litigation | Forfeiture [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Amount | $					5
Pending Litigation | Baby Powder [Member]
Legal Proceeding (Textuals)
Loss Contingency, New Claims Filed, Number	2
Investigative Demands [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Expense | $					$ 4
DePuy ASR U.S. | settled litigation
Legal Proceeding (Textuals)
Number of patients in settlement			8,000		8,000
Roche Diagnostics [Member]
Legal Proceeding (Textuals)
Loss Contingency, Patents Allegedly Infringed, Number | patents					2
Medinol Ltd. [Member]
Legal Proceeding (Textuals)
Loss Contingency, Patents Allegedly Infringed, Number | patents		4
DePuy ASR U.S.Second Agreement [Member] | Pending Litigation
Legal Proceeding (Textuals)
Number of patients in settlement			1,800		1,800
Medical Devices [Member]
Legal Proceeding (Textuals)
Litigation Settlement, Expense | $			$ 55	$ 409	$ 731

Restructuring (Details)

Restructuring (Details) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2016USD ($)	Sep. 27, 2015USD ($)	Oct. 02, 2016USD ($)Employee	Sep. 27, 2015USD ($)	Jan. 03, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 62	$ 0	$ 296	$ 0
Medical Devices [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	109		387
Restructuring charges recorded to date	977		$ 977
Period of workforce reduction			2 years
Number of positions eliminated | Employee			1,170
Medical Devices [Member] | Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3		$ 27
Medical Devices [Member] | Other Income Expense Net [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 44		64
Medical Devices [Member] | Asset Write-off [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			158
Medical Devices [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			229
Medical Devices [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost					$ 500
Restructuring charges			$ 0
Minimum [Member] | Medical Devices [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost					2,000
Positions eliminated (as a percent)			4.00%
Maximum [Member] | Medical Devices [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost					$ 2,400
Positions eliminated (as a percent)			6.00%

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 62	$ 0	$ 296	$ 0
Medical Devices [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning			501
Restructuring charges	109		387
Payments for Restructuring			(326)
Restructuring Reserve, Settled without Cash			(158)
Reserve balance ending	404		404
Medical Devices [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning			484
Restructuring charges			0
Payments for Restructuring			(81)
Restructuring Reserve, Settled without Cash			0
Reserve balance ending	403		403
Medical Devices [Member] | Asset Write-off [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning			0
Restructuring charges			158
Payments for Restructuring			0
Restructuring Reserve, Settled without Cash			(158)
Reserve balance ending	0		0
Medical Devices [Member] | Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Reserve balance beginning			17
Restructuring charges			229
Payments for Restructuring			(245)
Restructuring Reserve, Settled without Cash			0
Reserve balance ending	$ 1		$ 1